Table 2.

Long-term effectiveness of fluticasone propionate versus placebo in responders and nonresponders on exacerbations, health status, and lung function according to different international guidelines¹³–¹⁵

Variables		Total group	ERS		ATS		BTS
			Responders	Nonresponders	Responders	Nonresponders	Responders	Nonresponders
Exacerbations	FLU	0.98	0.71	0.93	0.56	0.96	0.63	0.95
(number/yr)	Pla	0.73	1.04	0.70	0.73	0.73	0.94	0.70
Rate ratio		1.30	0.68	1.33	0.77	1.32	0.67	1.36
Health status	FLU	+0.15	+0.30	+0.14	+0.29	+0.14	+0.29	+0.14
(points/yr)	Pla	+0.13	+0.01	+0.13	+0.09	+0.13	+0.03	+0.13
Annual difference (points)		+0.02	+0.29*	+0.01	+0.20	+0.01	+0.26	+0.01
FEV1-change	FLU	−59	−67	−58	−61	−59	−60	−59
(mL/yr)	Pla	−60	−97	−56	−69	−58	−99	−55
Annual difference (mL)		+1	+30	−2	+8	−1	+39	−4

Notes:

^*Statistical difference between responders and nonresponders, P < 0.05.

Abbreviations: ATS, American Thoracic society; BTS, British Thoracic Society; ERS, European Respiratory Society; FEV₁, forced expiratory volume in one second; FLU, ; Pla, platelets.